Literature DB >> 25687267

Prostate cancer: AR targeting--it all makes sense.

Louise Stone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25687267     DOI： 10.1038/nrurol.2015.26

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.

Authors:  Yoshiaki Yamamoto; Yohann Loriot; Eliana Beraldi; Fan Zhang; Alexander W Wyatt; Nader Al Nakouzi; Fan Mo; Tianyuan Zhou; Youngsoo Kim; Brett P Monia; A Robert MacLeod; Ladan Fazli; Yuzhuo Wang; Colin C Collins; Amina Zoubeidi; Martin Gleave
Journal:  Clin Cancer Res       Date:  2015-01-29       Impact factor: 12.531
  1 in total
  1 in total

1.  Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2α/C-MYC axis under hypoxia.

Authors:  W Zhai; Y Sun; M Jiang; M Wang; T A Gasiewicz; J Zheng; C Chang
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.